Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis
Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis
复制标题
纳米配方 ABT-199 可有效靶向线粒体膜上的 Bcl-2,通过诱导细胞凋亡减轻气道炎症
DOI:
10.1016/j.biomaterials.2018.06.020
复制
发表时间:
2019
期刊:
影响因子:
14
通讯作者:
Shen Huahao
中科院分区:
文献类型:
--
作者:
Tian Bao-Ping;Li Fangyuan;Li Ruiqing;Hu Xi;Lai Tian-Wen;Lu Jingxiong;Zhao Yun;Du Yang;Liang Zeyu;Zhu Chen;Shao Wei;Li Wen;Chen Zhi-Hua;Sun Xiaolian;Chen Xiaoyuan;Ying Songmin;Ling Daishun;Shen Huahao
Elimination of airway inflammatory cells is essential for asthma control. As Bcl-2 protein is highly expressed on the mitochondrial outer membrane in inflammatory cells, we chose a Bcl-2 inhibitor, ABT-199, which can inhibit airway inflammation and airway hyperresponsiveness by inducing inflammatory cell apoptosis. Herein, we synthesized a pH-sensitive nanoformulated Bcl-2 inhibitor (Nf-ABT-199) that could specifically deliver ABT-199 to the mitochondria of bronchial inflammatory cells. The proof-of-concept study of an inflammatory cell mitochondria-targeted therapy using Nf-ABT-199 was validated in a mouse model of allergic asthma. Nf-ABT-199 was proven to significantly alleviate airway inflammation by effectively inducing eosinophil apoptosis and inhibiting both inflammatory cell infiltration and mucus hypersecretion. In addition, the nanocarrier or Nf-ABT-199 showed no obvious influence on cell viability, airway epithelial barrier and liver function, implying excellent biocompatibility and with non-toxic effect. The nanoformulated Bcl-2 inhibitor Nf-ABT-199 accumulates in the mitochondria of inflammatory cells and efficiently alleviates allergic asthma.